{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-24-002523","form_type":"8-K","ticker":"HOWL","cik":"0001785530","company_name":"Werewolf Therapeutics, Inc.","filed_at":"2024-01-04T23:59:59+00:00","discovered_at":"2026-05-14T18:03:25.525818+00:00","generated_at":"2026-06-07T04:08:55.756328+00:00","sec_items":["5.02"],"event_type":"leadership","sentiment":"positive","materiality_score":0.6,"calibrated_materiality_score":0.6,"confidence":"high","headline":"Werewolf Therapeutics appoints Dr. Michael B. Atkins, cancer immunotherapy expert, to board","bullets":["Dr. Atkins appointed as Class III director effective Jan. 4, 2024; will serve until 2024 annual meeting.","He brings over 30 years of translational and clinical research in melanoma, kidney cancer, and immunotherapy.","Appointed to Nominating and Corporate Governance Committee.","Receives annual cash compensation of $40,000 plus $4,000 committee fee; granted option for 35,000 shares at $5.25.","Option vests one-third on first anniversary, then monthly over three years, subject to continued service."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-24-002523","json":"https://secwatch.observer/filing/0001193125-24-002523.json","markdown":"https://secwatch.observer/filing/0001193125-24-002523.md","text":"https://secwatch.observer/filing/0001193125-24-002523.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1785530/000119312524002523/0001193125-24-002523-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1785530/000119312524002523/d705253d8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-07T04:08:55.756328+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"9acd02a353","claim":"Michael B. Atkins was appointed as director at Werewolf Therapeutics, Inc..","evidence_excerpt":"On January 4, 2024, the Board of Directors (the “Board”) of Werewolf Therapeutics, Inc. (the “Company”), upon recommendation of the Board’s Nominating and Corporate Governance Committee, appointed Michael B. Atkins, M.D., as a director.","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1785530/000119312524002523/0001193125-24-002523-index.htm","confidence":0.95,"family_label":"Executive change","details":[{"label":"Action","value":"appointed"},{"label":"Role","value":"director"}],"fact_type":"executive_change"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}